The interval can be shortened in some circumstances (such as for people with increased risk of severe COVID-19) to 3 weeks for Pfizer original formulation and Novavax. The recommended interval between 2 doses of Pfizer original formulation or Novavax is 8 weeks. A longer interval may also improve vaccine protection. In children aged 6 months to less than 5 years, there is no clear attributable risk of myocarditis and pericarditis after COVID-19 vaccines.Ī longer interval between doses of the primary course may reduce the likelihood of myocarditis and pericarditis by a small amount. The risk also looks lower after a booster than the primary course. The risk of myocarditis and pericarditis is much lower in children aged 5 to 11 years compared to adolescents. Longer-term follow-up of these cases is ongoing. Most myocarditis and pericarditis cases linked to COVID-19 vaccination have been mild and patients have recovered quickly. There is no evidence to suggest myocarditis or percarditis is more severe following a particular brand of vaccine. The small number of total doses of Novavax given globally prevents the calculation of a precise risk as of February 2023.ĪTAGI will continue to monitor data as it emerges and update advice accordingly. This risk after AstraZeneca looked lower than the risk after Moderna original formulation or Pfizer original formulation. It is estimated there are around 2 more cases per 100,000 second vaccine doses in people under 40 who received Moderna original formulation than Pfizer original formulation.Įvidence suggests that AstraZeneca and Novavax are probably associated with a small increased risk of myocarditis and pericarditis. The risk of myocarditis is higher (although still rare) after vaccination with Moderna original formulation compared with Pfizer original formulation. Up-to-date information on cases and rates reported to the Therapeutic Goods Administration (TGA) is available in its COVID-19 vaccine safety reports. 1-3 The risk does not appear to be as high with booster doses compared with dose 2 of the primary course. The risk of myocarditis is highest in people aged 16 to 30 years (peak 16 to 18 years), and is higher in males than females. Myocarditis and pericarditis can also be caused by COVID-19. Not all cases that occur after vaccination are caused by the vaccine. Myocarditis and pericarditis occur in the general population from a variety of causes. Myocarditis and pericarditis can occur together or separately. Pericarditis is inflammation of the pericardium (the thin, sac-like tissue surrounding the heart muscle).Myocarditis is inflammation of the heart muscle.There is a link between COVID-19 vaccines and rare side effects of myocarditis and pericarditis. On this page Myocarditis and pericarditis
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |